Meningitis C immunisation timing updated

Children should now receive three doses of meningitis C vaccine: at 4 months, at 12–13 months (in combination with HiB) and at around 14 years of age | SCIENCE PHOTO LIBRARY
Children should now receive three doses of meningitis C vaccine: at 4 months, at 12–13 months (in combination with HiB) and at around 14 years of age | SCIENCE PHOTO LIBRARY

The recommended timing of routine vaccination for meningitis C has changed following new guidance from the Joint Committee on Vaccination and Immunisation (JCVI).

The booster dose of the vaccine that was previously given at 4 months should now be given at the same time as the adolescent tetanus, diphtheria and polio vaccine (around 14 years), to extend protection into early adulthood. The aim of the change is to make the meningitis C immunisation programme more effective and offer greater overall public health protection.

For the initial dose at 3 months, Menjugate Kit or NeisVac-C should be given; Meningitec should not be used because a single dose given in infancy does not provide adequate protection. All three products are suitable for the adolescent booster dose. 

For a quick-reference summary of the routine childhood immunisation schedule, see the MIMS table.

View meningitis vaccine drug records

Letter to healthcare professionals

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

MST Continus granules to be discontinued

MST Continus granules to be discontinued

All strengths of MST Continus (morphine) prolonged-release...

'Innovative' heart failure treatment recommended by NICE

'Innovative' heart failure treatment recommended by NICE

Dapagliflozin (Forxiga), the first SGLT2 inhibitor...